Incyte Corp. (INCY)

Company Description

Incyte Corporation (Wilmington, Delaware) is a biopharmaceutical company that is focused on developing novel small molecule therapies for the treatments of cancers and inflammatory diseases. The company obtained approval in the U.S. for Jakafi in late 2011, which is a first-in class compound for myeloproliferative disorders that inhibits the intraceullar Janus kinases (Jak) signaling pathway; the ex-U.S. ruxolitinib rights have been licensed to Novartis in a deal potentially valued at up to $1 billion. INCY’s second key pipeline product is INCB28050, which is a second-generation oral Jak inhibitor in development for autoimmune disorders such as rheumatoid arthritis. The company has licensed global rights to INCB28050 to Lilly, and plans to co-develop the agent in rheumatoid arthritis. Behind ruxolitinib and INCB28050, INCY has several earlierstage Phase I/II oncology assets, which have different mechanisms of action, and a fully owned second generation Jakafi.

 

COMPANY ADDRESS
Route 141 & Henry Clay Road
Wilmington, DE 19880
United States

COMPANY PHONE
302-498-6700

COMPANY WEBSITE



Get BioInvest's perspective on Incyte's CEO


Latest Company News

Incyte Corporation (INCY) Earns “Buy” Rating from JP Morgan Chase & Co BNB Daily (blog) - 3 hours ago Incyte Corporation logo J P Morgan Chase & Co reissued their buy rating on shares of Incyte Corporation (NASDAQ:INCY) in a research note issued to investors on Thursday morning. Incyte: Many Strengths, Small EPS, So What's It Worth? - Seeking Alpha Incyte Corporation (INCY) Stake Held by Eventide Asset Management LLC - The Cerbat Gem [...]
Wed, Feb 22, 2017 9:52:00 AM, Continue reading at the source
INCYTE CORPORATION (NASDAQ:INCY) Files An 8-K Entry into a Material Definitive ... Market Exclusive - Feb 21, 2017 Incyte Corporation (the “Company”) entered into a letter agreement, dated February 17, 2017 (the “Baker Exchange Agreement”) with certain entities (the “Baker Entities”) affiliated with Julian C. Baker, a director of the Company, to which the Baker ... [...]
Tue, Feb 21, 2017 12:56:00 PM, Continue reading at the source
Incyte's (INCY) Beats on Q4 Earnings, Provides 2017 Outlook Zacks.com - Feb 15, 2017 Incyte Corporation (INCY - Free Report) reported fourth-quarter earnings of 15 cents beating the Zacks Consensus Estimate of 14 cents. RBC Capital Mkts Just Issued “Outperform” Rating on Incyte Corporation (INCY) - Highland Mirror INCYTE CORPORATION (NASDAQ:INCY) Files An 8-K Results of Operations and ... - Market Exclusive [...]
Wed, Feb 15, 2017 6:00:00 PM, Continue reading at the source
Jakafi helps drive Incyte revenues over $1 billion Delaware Business Times - Feb 14, 2017 Incyte Corporation, one of the region's largest pharmaceutical companies, today reported fourth-quarter and year-end financial gains for 2016. Incyte Corporation: Incyte Reports 2016 Fourth-Quarter and Year-End Financial ... - The Wall Street Transcript Incyte (INCY) Q4 2016 Results - Earnings Call Transcript - Seeking Alpha [...]
Tue, Feb 14, 2017 8:36:00 PM, Continue reading at the source
Agenus Gets A Boost From Incyte Cash Infusion Benzinga - Feb 14, 2017 Investors are encouraged that Incyte Corporation (NASDAQ: INCY) has amended a collaboration deal for development and commercialization responsibilities for GITR and OX40. Incyte and Agenus Amend Collaboration Agreement - Yahoo Finance Agenus Inc. (NASDAQ:AGEN) Deal With Incyte Corp. (INCY) Looks Good - StockNewsUnion [...]
Tue, Feb 14, 2017 4:52:00 PM, Continue reading at the source
Incyte Corporation Bottom Line Falls 84% In Q4 Nasdaq - Feb 14, 2017 (RTTNews.com) - Incyte Corporation ( INCY ) revealed earnings for fourth quarter that declined from last year. The company said its earnings came in at $8.87 million, or $0.05 per share. [...]
Tue, Feb 14, 2017 12:00:00 PM, Continue reading at the source
Should You Sell Incyte (INCY) Before Earnings? February 13, 2017 Zacks.com - Feb 13, 2017 Investors are always looking for stocks that are poised to beat at earnings season and Incyte Corporation (INCY - Free Report) may be one such company. [...]
Mon, Feb 13, 2017 1:52:00 PM, Continue reading at the source
Incyte Corporation (INCY) Moves Higher on Volume Spike for February 08 Equities.com - Feb 8, 2017 Incyte Corporation (INCY) traded on unusually high volume on Feb. 08, as the stock gained 3.85% to close at $122.73. On the day, Incyte Corporation saw 2.16 million shares trade hands on 16,600 trades. Considering that the stock averages only a daily ... Recent analysts Ratings: Incyte Corporation (NASDAQ:INCY) - News Oracle Can Incyte Corporation (NASDAQ:INCY) grow after Earnings? - FactsReporter [...]
Wed, Feb 08, 2017 10:30:00 PM, Continue reading at the source
Incyte Corporation Realized Volatility Hits An Amplified Level CML News - Feb 4, 2017 This is a proprietary realized volatility rating created by Capital Market Laboratories (CMLviz) based on a large number of data interactions for Incyte Corporation (NASDAQ:INCY) . We examine the little used gem of daily stock volatility over a 20-day ... [...]
Sat, Feb 04, 2017 3:22:00 PM, Continue reading at the source
Incyte Gives Calithera A New Lease Of Life Seeking Alpha - Feb 1, 2017 stock languishing 56% off its float price and 85% below its peak two years ago the company needed a new lease of life, and got it yesterday via a licensing deal with Incyte (NASDAQ:INCY) on CB-1158, an asset to which few had paid much attention. Incyte and Calithera Enter into Deal for Oncology Candidate - Zacks.com Incyte and Calithera Biosciences Announce Global Collaboration to Develop and ... - Yahoo Finance [...]
Wed, Feb 01, 2017 4:07:00 PM, Continue reading at the source